Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

NEW ORLEANS, Dec. 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. There were seven presentations of clinical data, of which five were oral presentations, including one "Best of ASH" presentation on Waldenstrom's macroglobulinemia (WM). In total, 33 additional pre-clinical and non-clinical presentations provided new discoveries using ibrutinib; seven of these were oral presentations. The presentations further elucidated the mechanism of action of ibrutinib and its effect in the tumor microenvironment and provided data on quality of life changes. Results covered various B-cell malignancies: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), WM, and non-Hodgkin lymphoma (NHL).

"The breadth of data presented at ASH this year demonstrates the scientific community's interest in ibrutinib and builds on the clinical responses seen with ibrutinib as a backbone of combination therapy and as a single agent in multiple B-cell malignancies," said Jesse McGreivy, M.D., Chief Medical Officer, Pharmacyclics. "This year's data explain ibrutinib's effect on the quality of life for patients and build on impressive efficacy and safety results, independent of cytogenetic risk factors. We also now have long-term follow-up in CLL, which suggests continuation of the efficacy and a decrease in overall and severe adverse events."

Clinical Trial Presentation Highlights

Chronic Lymphocytic Leukemia

-POSTER PRESENTATION- Abstract #4163:
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibruti
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 2011 Phreesia, the patient check-in company, today ... health records (EHR) software and solutions, has been ... partnership, medical practices nationwide that use both SOAPware ... seamless patient check-in experience. The automated interface between ...
... 18, 2011 Ohio-based AdCare Health Systems, Inc. ... Remedi SeniorCare®, one of the nation,s largest institutional ... services for AdCare,s facilities  that deliver long-term care ... Remedi pharmacy services will include pharmacist ...
Cached Medicine Technology:Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 2Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 3AdCare Health Systems Selects Remedi SeniorCare for Long-Term Care Pharmacy Solutions 2AdCare Health Systems Selects Remedi SeniorCare for Long-Term Care Pharmacy Solutions 3
(Date:4/22/2014)... computational tool developed at the University of Utah (U ... mutations in three separate cases, U of U researchers ... The American Journal of Human Genetics . The ... undiagnosed illnesses and unknown gene mutations by analyzing the ... for genes are made, in individual patients and small ...
(Date:4/22/2014)... cell lung cancer are 70 years of age or ... are not well represented in clinical trials. Therefore, the ... reach evidence based clinical recommendations. , In 2010, the ... Cancer Group along with the International Society for Geriatric ... for elderly patients with non-small cell lung cancer (NSCLC), ...
(Date:4/22/2014)... -- When mothers are exposed to trauma, illness, alcohol ... single molecular trigger in brain cells that can go ... disorder and some forms of autism. , Until now, ... impacted the cells of a developing brain. Past studies ... to alcohol or drug abuse or she experiences some ...
(Date:4/22/2014)... (April 22, 2014) Cedars-Sinai stroke intervention researchers have ... and Stroke, part of the National Institutes of Health, ... multicenter Phase II clinical trial of an experimental drug ... used in combination with recombinant tissue plasminogen activator, or ... ischemic strokes shortly after onset. In laboratory rodent studies, ...
(Date:4/22/2014)... on results of a clinical trial led by ... Drug Administration (FDA) approved a molecularly targeted drug ... has progressed after standard chemotherapy has failed. , ... announced by the manufacturer, Lilly Oncology, of Indianapolis. ... it will be sold under the name Cyramza, ...
Breaking Medicine News(10 mins):Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2
... lead character smokes is not as effective a method as ... the appeal of smoking to , are non-smokers. ... the June issue of the journal Tobacco Control. ... whom were current smokers, aged 12-24 years in Australia, over ...
... found that diabetes is associated with decreases in life expectancy, ... ,The study, published in Archives of Internal Medicine, ... with diabetes at age 50 and older appear not to ... without cardiovascular disease, than individuals without diabetes. ,Globalization ...
... Just a short walk from some of Tokyo's most chic ... for long, if the government gets its way . In ... baskets loaded with their fresh catch at Tsukiji market, minutes ... luxury shops and corporate headquarters. The world's largest ...
... disease in monkeys with the help of human stem cell ... in the Proceedings of the National Academy of Sciences, the ... and grew them into large numbers in the laboratory. ... of monkeys with a severe form of chemically induced Parkinson's ...
... ballet shoe are booming in Britain, where the latest unusual ... environment . Since 2000, Vic Fearn and Company have been ... Coffins". The firm recently expanded their range to ... from the clients," said John Gill, head of the Nottingham, ...
... is dumped in Urali Devachi, about 25 kilometers from the ... villagers . ,Urali Devachi village has been turned into ... the citys nearly five million plus population. ,The ... to Urali Devachi, located on Pune-Saswad road, in 1999. ...
Cached Medicine News:Health News:Diabetes Reduces Life Expectancy, Increases Heart Disease Risk 2Health News:Traders Smell Something Fishy in Tokyo Market Move 2Health News:Traders Smell Something Fishy in Tokyo Market Move 3Health News:To Die For: Rolls-Royce and 'green' Coffins at British Funerals 2
Inquire...
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
... Mo Bio Vortex Adapter in conjunction with the ... Using the Mo Bio Vortex Adapter is ... Fast Prep machines which offer the same technology. ... centrifuge tubes at one time and will fit ...
Medicine Products: